Personalis price to sales ratio PSNL

Market value divided by revenue over the last twelve months, since 2020.

Today, Oct 23, 2026: 24.3×
7-year median: 4.9×
Against its 7-year history: 97th; percentile: 0 is its lowest day, 100 its highest
7-year range: 0.7× to 28.2×
Peer median: 6.9×

Personalis' price to sales ratio is 24.3× as of Oct 23, 2026.

That is above its 7-year median of 4.9×, higher than on 97% of days in the last 7 years.

Over that time it ranged from 0.7× in Oct 2023 to 28.2× in Aug 2026.

The median for 7 diagnostics and research stocks of a similar size is 6.9×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	24.3×	8.7×	28.2×
2025	10.5×	3.2×	13.8×
2024	4.7×	0.8×	4.7×
2023	1.5×	0.7×	2.6×
2022	1.3×	1.3×	6.8×
2021	7.5×	6.4×	24.3×
2020	18.6×	3.4×	21.1×

Against its peers

Companies in Medical - Diagnostics & Research nearest Personalis' size, closest first, today.

Company	Price to sales ratio
PSNLPersonalis	24.3×
CDNACareDx	7.8×
VCYTVeracyte	6.9×
BLLNBillionToOne	12.8×
NRCNRC Health	3.5×
LNTHLantheus	4.2×
CAICaris Life Sciences	9.1×
BIOBio-Rad Laboratories	3.8×
Peer median	6.9×

Where Personalis ranks

#57of 61Diagnostics and research stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Personalis

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.